Work

Less is more: Low-strength type I interferon signaling enhances CAR T cell therapy

Year: 2026

Type: article

Abstract: Current CAR T cell therapies produce durable remissions in B cell malignancies, yet primary resistance and relapse remain major challenges.1,2 Most efforts to improve efficacy have focused on the receptor or the genome encoding it, through new receptor and costimulatory designs, additional genetic modifications, rewiring of intracellular signaling, phenotype-directed differentiation, or combination regimens.3 These strategies are powerful, but most introduce a new genetic element or a novel biologic agent and with it, a new engineering, manufacturing, and regulatory burden.

Source: Molecular Therapy Oncology

DOI: 10.1016/j.omton.2026.201351

Authors: Erting Tang, Jun Huang

Institution: University of Chicago

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,900